NCT05107219View on ClinicalTrials.gov

GCC Agonist Signal in the Small Intestine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Barrett EsophagusGastroesophageal Reflux DiseaseMalignant Digestive System Neoplasm
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of luminal fluid

PROCEDURE

Esophagogastroduodenoscopy

Undergo EGD

DRUG

Linaclotide

Given PO

DRUG

Plecanatide

Given PO

Trial Locations (4)

19107

Thomas Jefferson University Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER